Correspondence 0001193125-23-130597 from ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858) (SPRY)
ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858)
Date: May 1, 2023 · CIK: 0001671858 · Accession: 0001193125-23-130597
AI Filing Summary & Sentiment
File numbers found in text: 333-271359
Letter
ARS Pharmaceuticals, Inc.
11682 El Camino Real, Suite 120
San Diego, California 92130
May 1, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Joshua Gorsky
Re: ARS Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-271359
Acceleration Request
Requested Date:
Wednesday, May 3, 2023
Requested Time:
4:30 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, ARS Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on Wednesday, May 3, 2023, at 4:30 P.M. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth J. Rollins of Cooley LLP at (858) 550-6136 or Asa M. Henin of Cooley LLP at (858) 550-6104. Thank you for your assistance with this matter.
Sincerely,
ARS Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, California 92130 May 1, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joshua Gorsky Re: ARS Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-271359 Acceleration Request Requested Date: Wednesday, May 3, 2023 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, ARS Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on Wednesday, May 3, 2023, at 4:30 P.M. Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth J. Rollins of Cooley LLP at (858) 550-6136 or Asa M. Henin of Cooley LLP at (858) 550-6104. Thank you for your assistance with this matter. Sincerely, ARS Pharmaceuticals, Inc. By: /s/ Alexander A. Fitzpatrick Alexander A. Fitzpatrick, Esq. Chief Legal Officer cc: Richard Lowenthal, M.S., MBA, ARS Pharmaceuticals, Inc. Kenneth J. Rollins, Cooley LLP Asa M. Henin, Cooley LLP